مجانا ... بيتر ليدز

[Sniper]

AIMM today released their financial results for the third fiscal quarter ended September 30, 2003. The company reported a net loss of $0.16 million, for the three months ended September 30, 2003, compared with a net loss of $0.25 million, for the three months ended September 30, 2002.

For the nine months ended September 30, 2003, net income was $0.74 million, compared with a net loss of $0.64 million, for the nine months ended September 30, 2002. Results for the nine months ended September 30, 2003 reflect receipt of the final payment in March 2003 from a subsidiary of Elan Corporation plc for its purchase of AIMM’s rights to certain patent applications.

This past quarter Colloral LLC, AIMM’s joint venture with Deseret Laboratories International, began market testing in geographically limited areas several approaches to increase the sales of Colloral®, its product for nutritional support of patients with rheumatoid arthritis.

BioMS has confirmed that it expects to begin an advanced phase clinical trial of a novel treatment for chronic progressive multiple sclerosis, which utilizes intellectual property rights exclusively licensed from AIMM, within the next several months. BioMS makes monthly diligence payments to AIMM and has a royalty obligation on sales of the product should it reach the market.

Teva Pharmaceutical Industries, Ltd. reports that during the first quarter of 2004 it hopes to begin the next human clinical studies on an oral formulation of COPAXONE®, a product for the treatment of multiple sclerosis, which utilizes intellectual property rights exclusively licensed from AIMM. If Teva is successful in bringing this product to market, AIMM will receive both a milestone payment and a royalty on sales.

[Sniper]

هلا والله آينشتاين وشكرا لمرورك ...

أنا والله جديد على بيتر ، أعتقد انه يعتمد على الخبر بدرجه أولى بالاضافه للتحليل ، لكنه مش مثل لاري سوينغ اعتماده فقط على التحليل ، فأنا أشوفه يورد اخبار عن الشركات مع متابعه لتاريخ الشركه والتنويه اذا كانت الشركه مسويه هاي أو ما الى ذلك .. لكن الخبر على ما رأيت للآن طاغي على التحليل و مع الوقت حتما راح تضح لنا الرؤيا جميعا ..


AF today announced that it has closed its fiscal year with record annual new alarm installations of 9,500 new subscribers, bringing the total monitored account base to over 42,000 subscribers.
Joel Matlin, President & CEO, announced the record numbers, adding, "In the home alarm industry the account base is the key driver of recurring revenues and profit performance. We created record new accounts in the major market centres in Canada during 2003, all through organic growth and increasing our monthly recurring revenues to the highest level since the inception of our company fifteen years ago."


"Our financial results for 2003 will be impressive, reflecting the record growth in the numbers. At the beginning of this year we predicted to our shareholders that 2003 would be the best year ever in our history, and I am happy to say that indeed we are on track."
With respect to future outlook, Mr. Matlin added, "I am convinced that what lies ahead for the company will be phenomenal, given our success in reaching new customers."

In early morning trading AF’s share price rose 8.4% to an intra-day high of $3.09. The company is currently trading up 13 cents over yesterday’s close at $2.98 on 24,000 shares.

[Sniper]

Yesterday ADSX announced that its wholly owned subsidiary, VeriChip Corporation, has received a purchase order for 400 VeriChips and 34 handheld scanners from its exclusive distributor for Russia and Switzerland. These VeriChip sales represent the first to countries in the European region.

The Swiss Russian distributor, RussGPS, has offices in Moscow and Zurich and operates throughout the GUS (former Soviet Union) region. Under the terms of the distribution agreement, the distributor has agreed to purchase a total of 1,000 VeriChips and 100 proprietary scanners in 2003. Over the five years covered by the agreement, the minimum purchase requirement is 51,000 VeriChips and 2,600 proprietary scanners in order to maintain exclusive distribution rights in the stipulated countries.

Before the press release ADSX was trading for 43 cents; after the press release the company’s share price rose 10.4% to an intra-day high of 48 cents. ADSX closed the day trading at 47 cents on over 40,000,000 shares; more than 4 times the daily average.

The company is currently trading for 42 cents on 15,800,000 shares.

[Sniper]

بيتر ليدز - مثل ما أشار في الموقع- يرشح اسبوعيا سهمين : واحد الثلاثاء وواحد ثاني الخميس.

الترشيح يتم بين 7 الى 10 مساءا EST ..

انشاء الله سيتم طرحهم في أقرب وقت ..


وفق الله الجميع

[Sniper]

PRZ
PainCare Holdings, Inc.
November 11th Market: AMEX
Profile Price: $2.40
Buy Opinion: 2.40 - 2.50
Short-term Sell: 3.00 - 3.20

Highlights
PRZ is a global leader in an industry that generated $100 billion in 2002.

In the third quarter PRZ realized revenue growth of 154%

In August PRZ reported second quarter revenue growth of 111.2%

PRZ just recently welcomed their 22nd Med-X rehab partner



Outlook- PainCare Holdings Inc. (PRZ) is a young, innovative, profitable company that is quickly establishing itself as the pioneering leaders in the lucrative Pain Management market – a market segment that collectively generated $100 billion dollars last year. Their revenues are skyrocketing, their distribution base is expanding and they have an aggressive acquisition strategy.

A 1999 report by the investment firm Stifel, Nicolaus & Company, Inc. reported that back pain is the #1 reason for doctor office visits in the United States and the #1 ailment in worker’s compensation claims. About 35% of all orthopedic hospital admissions are spine related and more than 220 spinal conditions, indications, and pathologies afflict patients.

PRZ’s minimally invasive surgery and innovative approach to pain management creates a unique trading opportunity for investors. The minimally invasive surgery is a less traumatic, cost effective alternative for patients; it reduces the cost for insurance companies by up to 40% versus traditional therapies; and it has the potential to significantly increase the net income of participating physicians.

In their report, Stifel, Nicolaus & Company, Inc. state, "Clearly the market is moving towards minimally invasive procedures and technologies... We believe that in order to be successful in the future, companies will have to employ minimally invasive concepts..."

A company with excellent long-term growth potential,
PRZ is uniquely positioned to succeed.


Business Profile - PRZ is a high-tech healthcare services company that owns, manages and operates a network of pain management, rehabilitation centers across North America.

The company has developed a "Three Pillar" business approach to provide an integrated combination of products and services to patients seeking pain relief. These "Three Pillars" include, Pain Management, Minimally Invasive Spine Surgery (MIS) and, Orthopedic Rehabilitation.

MIS or "band-aid" surgery is a specialized surgical technique based on currently available endoscopic technologies, which allows physicians to provide the most technically advanced treatment of back and neck pain in an outpatient environment.

Orthopedic Rehabilitation is a comprehensive program that advances functional restoration of the musculoskeletal system utilizing the company’s proprietary, state of the art computerized Med-X medical exercise machines.


To date, PRZ has deployed or is in the process of deploying nearly two-dozen Med-X Direct Programs throughout North America. Moreover, PRZ is in active discussions and negotiations with nearly 100 additional practices that have expressed interest in integrating the Med-X Direct Rehabilitation Program into their practices.

Fundamental Analysis - On Tuesday, November 11, 2003 PRZ announced their fiscal results for the third quarter ended September 30, 2003. Revenues for the third quarter increased 154% to $4,376,417 from $1,720,419 reported in the same period last year. The company's gross profits nearly doubled (177%) to $3,010,754 from $1,086,939; this was due in large part to increases in gross profit margins which rose to 69% from 63%.


Randy Lubinsky, CEO of PRZ, stated, "PainCare continues to successfully build upon the framework we established three years ago when we founded the Company. We believe that our ability to consistently demonstrate successive quarter-over-quarter growth in all operational areas is a direct reflection of our strict adherence to set business principles and the consistent execution of our business plan."
And back in August the company announced their fiscal results for the second quarter ended June 30, 2003. Revenues for the quarter increased 111.2% to $3,774,487 over the comparable period in 2002, while the company’s gross profits increased 131% to $2,727,671. This increase was primarily due to the acquisitions of Pain and Rehabilitation Network and Medical Rehabilitation Specialists, along with the opening of new Med-X Direct rehabilitation centers.

Based on the financial performance of the company to date and the successful execution of its growth plan, management believes that PRZ could achieve annual revenues of $62 million and net income of $13 million by the end of fiscal year 2005.


Recent News - On November 6 the company announced that Orthopedics & Sports Medicine, LLC, based in Bedford, Indiana, has contracted with PRZ to offer the company’s proprietary MedX-Direct on-site orthopedic rehabilitation program to patients in Southern Indiana.

The founder of the practice, Harlen C. Hunter, D.O., is industry renowned for his pioneering work in orthopedic surgery and is one of a limited number of surgeons trained and certified to perform cartilage regeneration surgery and a special, new alternative to total knee replacement.


Ronald Riewold, President of PRZ, stated, "We are very pleased to welcome Dr. Hunter to our growing network of MedX-Direct partners, one who many in the Midwest refer to as 'the Father of Sports Medicine.' In consideration of Dr. Hunter's noted reputation as a leader in orthopedic and sports medicine, his decision to deploy MedX-Direct onsite at his private practice reinforces that medical specialists recognize that MedX is indeed the gold standard in muscular-skeletal rehabilitation."
On September 22 PRZ announced that in response to strong and growing demand from its national network of pain management practices and MedX-Direct rehabilitation program partners, the company has formed PainCare Surgical Centers, Inc., a wholly-owned subsidiary established for the purpose of acquiring, developing and operating high-tech, outpatient surgical centers dedicated to performing minimally invasive spine surgery and associated pain management procedures.


Randy Lubinsky, CEO of PRZ, stated, "The prospect of adding outpatient surgery centers to our business mix is being driven by unrelenting demand from our physicians, the tens of thousands of patients that we serve directly or indirectly through our MedX-Direct programs…We fully expect that this business expansion will result in notable revenue and earnings growth for PainCare as we deploy each new center."
And on September 15, PRZ welcomed Vero Beach, Florida’s ProSports, the 22nd medical practice in the country to partner with PRZ to directly avail comprehensive musculoskeletal rehabilitation to its patients.


Conclusion - PRZ is a young, innovative, profitable company that is rapidly becoming established as the pioneering leaders in the lucrative Pain Management market. Their revenues are skyrocketing, their distribution base is expanding and they have an aggressive acquisition strategy.

PRX also has enviable assets: a highly regarded brand name in MedX-Direct; a hard-earned reputation for integrity and reliability; a growing North American network of well-established, highly profitable medical practices; and a dedicated team of knowledgeable, experienced medical, financial and business professionals.

To ensure continued growth PRZ will persist in acquiring targeted Pain Medicine and Orthopedic practices; introduce a comprehensive selection of MIS and other techniques through affiliated health centers; and integrate and capitalize on the demographics of the target market.

PRZ remains committed to implementing a business strategy that will position the company as the world leader in pain management, minimally invasive spine surgery and orthopedic rehabilitation. A company with excellent long-term growth potential, PRZ is uniquely positioned to produce superior returns to their shareholders.






وبالتوفيق

[Sniper]

PRZ ارتفعت اليوم 8% ...

هذي ماهي توصيه شراء .. أتمنى التبرع بالتحليل من قبل الزملاء

[Sniper]

STG today reported financial results for the three and nine months ended September 30, 2003.


Highlights
Third quarter revenue rose 76.3%

For the nine months, revenue increased 97.6%
For the third quarter of 2003, STG reported revenues of $77.3 million, up from $43.9 million for the same prior year period, an increase of $33.4 million or 76.3%. For the nine months ended September 30, 2003, STG reported revenues of $177.1 million, up from $89.6 million for the same prior year period, an increase of $87.5 million or 97.6%.


"It remains a busy and productive time for Stonepath", said Dennis Pelino, the company's CEO. "We continue to make good strides in delivering top-line growth as we build our network. Our 2003 revenue target of $210 million appears to be well within reach…Our acquisition strategy, coupled with a focus on organic growth, technology, integration, cost control and EBITDA growth is working, creating value for our shareholders and our customers."
Pelino continued: "Overall, I remain very bullish on the direction of the Company. Having started from zero a little over two years ago, we should deliver well over $200 million in revenues in 2003 and continue to expand the footprint of our service delivery platform…We look forward to reporting our continued progress."

In early trading today STG rose 11 cents to an intra-day high of $2.90; the company is currently trading for $2.87 on 172,300 shares.

[Sniper]

Before the markets opened today FTGX announced its fiscal results for the third quarter ended September 30, 2003. The company's performance was highlighted by the acceleration of revenue growth in the third quarter of 2003 compared to the second quarter of 2003. FTGX has now produced increases in revenues in the last four consecutive quarters. The company also generated positive cash flow from operations for the first nine months of 2003.

Revenues for the third quarter of 2003 increased to $6.7 million, up 4% from $6.5 million for the second quarter of 2003 and up 14% from $5.9 million for the third quarter of 2002. In its core product offerings of transport and colocation services, FTGX experienced even greater revenue growth. For the third quarter of 2003, revenues from transport and colocation grew by 5% over the second quarter of 2003 and by 20% over the third quarter of last year.

Michael S. Liss, President and CEO, remarked, "The tone of our business is improving with the industry. The top-line growth that we are experiencing is coming from delivering our core transport and colocation product offerings to Tier 1 domestic and international carriers. Our overall results support our optimism for telecommunications in general, but more specifically for the metro segment of the marketplace."

In early trading FTGX’s share price rose 21% to an intra-day high of $1.63. The company is currently trading for $1.48 on 1,227,000 shares.

[Sniper]

PRZ today announced that the company has contracted with Vissman Therapeutics, a Pittsburgh-based group of physical therapy centers, to deploy PainCare's MedX-Direct Rehabilitation Program on-site at one of its facilities located in Canonburg, Pennsylvania.

Dr. Shannon Vissman stated, "We are very pleased to be partnering with PainCare to deliver state-of-the-art musculoskeletal rehabilitation using what we believe is the very best equipment on the market today. Although we will be deploying PainCare's MedX- Direct program in only one of our facilities initially, it is our intent to universally replace all existing ortho rehab equipment in each of our facilities with nothing but MedX machines."

[Sniper]

TTP announced today positive preclinical results demonstrating that continuous drug delivery using the company's ProNeura technology reduced the risk of motor symptoms in a validated primate model of Parkinson's disease. The study results were presented today in New Orleans at the Society for Neuroscience 33rd Annual Meeting.

TTP's ProNeura technology is a copolymer based implant into which a therapeutic drug is incorporated. The implant is placed under the skin, allowing the drug to be delivered appropriately at a consistent level over an extended period.


"These results suggest that this delivery system can overcome the potential side effects of standard dosing regimens to provide a better treatment for Parkinson's disease," said Dr. Thomas N. Chase, principal investigator for the study. "This method of releasing a steady and constant amount of dopamine agonists is the first of its kind and represents an important step towards improving the quality of life of Parkinson's patients."
"These results are encouraging," stated Louis R. Bucalo, M.D., Chairman, President and CEO of TTP, "and provide a potential expansion of Titan's continued commitment to improved treatment of Parkinson's disease. Our next steps are to evaluate the possible suitability of various dopamine agonists for incorporation into our ProNeura technology."

In trading today TTP’s share price rose 14 cents to an intra-day high of $2.94; the company is currently trading for $2.90 on 69,400 shares.

[Sniper]

JADE announced today that it will be one of the featured companies in BusinessWeek's Equity Investor's 26-Week Micro-Cap Review, to be published in the magazine's December 15th issue.

Companies were chosen for the semi-annual Micro-Cap Review on the basis of their percentage gain in stock price for the six-month period ending September 30, 2003. JADE ranked in the top 7% of BusinessWeek's Micro-Cap survey. During the period covered by the survey, the company’s share price rose over 320%, from $1.25 to $4.00.


''The fact that investors have raised the price of LJ International shares more than three-fold in the latest six-month period is a reflection of the investment community's increased interest in LJ International and, perhaps more importantly, our potential for future growth,'' said Yu Chuan Yih, Chairman and CEO of JADE.
We first introduced you to JADE back on April 22 when the company was trading for $1.20. Since then JADE’s share price has risen 337.5% to a high of $5.25. The company is currently trading up 23 cents over yesterday’s close at $4.44 on 45,400 shares.

[Sniper]

Market acceptance and penetration efforts continue as DPAC announces two more design wins today for the new line of 802.11b wireless modules called Airborne. The first of these is an application of wireless 802.11b technology into medical instrumentation that measures and monitors physiological responses; the second is an industrial application for a Homeland Security "First-response" system.


"This added success into two more of our target vertical markets is indicative of the strong interest we are experiencing with prospective customers", said Brett Trowbridge, VP for DPAC. "Both the medical and the industrial markets provide significant opportunities for the Airborne product that DPAC will continue to pursue aggressively."

[بن فهد]

اللهيجزاكالفخيريارب

اللهيجزاكالفخيريارب

اللهيجزاكالفخيريارب

اللهيجزاكالفخيريارب

اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب
اللهيجزاكالفخيريارب

[Sniper]

هلا والله بالغالي حنوووووووون

شكرا على مرورك أخوي

وما سويت شي يذكر مقارنه فيك و باقي اخواننا في المنتدى ...

خيركم ساق يالغالي .


تحياتي

[المحيط العميق]

أخي سنيبر مجهود أكثر من رائع.

بالنسبة للتوصيات هل تشتري مباشرة بعد التوصية بمعنى هل يرتفع السهم مباشرة بعد التوصية أم ماذا؟
وهل من الممكن وضع عنوان الموقع. وشكرا لك.

[Sniper]

شكرا على مرورك أخوي ..

هم عاده يحطون مدى يعني يحطون توصيه اشتر من كذا لكذا ونتوقع الوصول من كذا لكذا..

الوصول للهدف حقهم - حسب ما رأيت للآن- يتراوح من شهرين الى 3 شهور حتى يحقق الهدف الموضوع و أحيانا أقل من شهر .

يعني يعتمد بس يبغاله واحد صبور شوي مش مضارب يومي....

و عنوان موقعهم هو :

http://www.peterleeds.com/index.html

وشكرا مره أخرى على مرورك أخوي

[Sniper]

November 13, 2003.


Highlights
CYRO is a leading provider of broadcast graphics hardware and software

Their graphics products make up over 70% of the live broadcast tools in the U.S.

For the first six months of 2003 net sales rose 3%, while net loss fell 82%

CYRO’s products are used by ABC, CBC, FOX, CBS, CNN, ESPN, and BBC

ABC uses CYRO's HDTV Graphics for the Super Bowl, NBA Finals, and Stanley Cup


Outlook- A streamlined, focused company with an excellent future, Chyron Corporation (CYRO) is the unrivaled leader of broadcast graphics used in digital TV. CYRO develops, manufactures, markets and supports hardware and software products that enhance the production values of live and pre-recorded video, audio and other data.

With a strong presence in the broadcast TV media industry, CYRO’s graphics products specialize in the real time arena and make up over 70% of the installed base of such tools for live broadcast in the U.S.

And with their pulse on the future of the communication age, CYRO continues to sustain its role of market leadership by maintaining a focus on Enhanced and Interactive TV, which could develop rapidly along side the advent of Digital TV.


Business Profile - If you’ve ever watched TV…you’ve seen CYRO’s products in action. CYRO develops products that create, store and manipulate text, logo and other graphics images using special effects such as 3D transforming, compositing and painting for use in digital television.

CYRO’s graphics products are used by most broadcasters in the US and many around the world including ABC, FOX, CBS, ESPN, CNN, CBC, and the BBC to display such information as sports scores, logos, news flashes, weather flashes, election results and stock market quotes.


CYRO graphics products specialize in the real time arena and make up over 70% of the installed base of tools for live broadcast in the U.S.
Even though CYRO’s graphics products have cornered the broadcast market in the U.S., there is still plenty of room to grow in the ever evolving world of television. To keep abreast of the competition CYRO has been focusing on what they believe to be the future of the communication age: Enhanced and Interactive TV.

Interactive TV merges traditional television with Interactive graphics and information, allowing consumers to interact with programming. Whether they're matching wits with contestants on game shows, voting in live polls, accessing entertainment/sports/news headlines, chatting live with other viewers, or accessing e-mail - all will be done through television.

And CYRO hopes to corner this inevitable market with iTV. iTV offers opportunity for significant revenue from Interactive advertising, t-commerce and increased viewer retention; and that’s something that every production team will want a piece of.

Fundamental Analysis - On August 7 CYRO announced their fiscal results for the second quarter ended June 30, 2003. Total revenue for the second quarter ended June 30, 2003 was $10.0 million, a decrease of $0.3 million or 3%, as compared to $10.3 million for the same quarter last year. For the first six months of 2003, total revenue was $20.9 million, an increase of $0.5 million or 3% as compared to $20.4 million for the first six months of last year.

CYRO reported a net loss for the second quarter of $0.4 million, as compared to a net loss of $1.0 million for the second quarter of 2002. For the first six months of 2003 the company reported a net loss of $0.3 million, as compared to a net loss of $1.8 million for the first six months of last year.

Michael Wellesley-Wesley, CYRO’s President and CEO, commented: "Chyron's second quarter performance was satisfactory. I am pleased with the year over year improvement in gross margins and the fact that our continued emphasis on tight cost control resulted in lower operating expenses compared with the prior year period."


"The Company is now consistently generating cash from operations and any improvement over first half revenue levels through the balance of 2003 will directly benefit the bottom line. We continue to believe that we are in the early stages of a recovery in broadcast

Recent News - On November 11 CYRO announced the appointment of Bill Hendler as VP, Chief Products Officer. In his new role, Hendler will be responsible for overseeing product management for CYRO’s hardware and software products.

Commenting on the appointment, CYRO's CEO Michael Wellesley-Wesley said, “Bill…has been instrumental in directing and implementing Chyron’s innovative technology through the years. He has an exceptional depth of understanding of both the television market and the products necessary for Chyron to continue its leadership role.”

On November 6, 2003 CYRO announced the sale of all of the stock in its wholly-owned subsidiary Chyron UK Holdings Limited and its operating subsidiary Pro-Bel Limited which constituted all of the company's signal distribution and automation business.

Gross proceeds were approximately $15.6 million before the required settlement of Pro-Bel bank obligations of approximately $2.8 million, resulting in net proceeds to the company of approximately $12.8 million before transaction related costs. The company's preliminary estimate of gain on the sale is approximately $2.5 million and will be recorded in the fourth quarter.


Michael Wellesley-Wesley, CYRO’s CEO commented "The proceeds from the sale of Pro-Bel will enable us to significantly reduce our debt. Chyron is now able to focus 100% on our core competency, the development of real-time graphics solutions for our professional video and TV broadcast customers around the world."

Conclusion - A streamlined, focused leader of broadcast graphics used in digital TV, CYRO has an insurmountable edge over their competition. With a strong presence in the broadcast TV media industry, CYRO’s graphics products specialize in the real time arena and make up over 70% of the installed base of such tools for live broadcast in the U.S.

Not content with their current market domination, the company continues to sustain its role of market leadership by maintaining a focus on Enhanced and Interactive TV, which the company believes will develop with the advent of Digital TV.

Our cultures undying love of electronics and technology will inevitably usher in the wide spread acceptance of Digital TV. It is not science fiction to think that in the near future we will interact with others on our TV’s, choose the news we want to see, and vote for our “favorite” politician. And it could be CYRO that pilots this interactive revolution of the communication age.

But for now, a recovery in broadcast capital spending coupled with the insatiable need for innovative graphic products for use on the Internet virtually assures CYRO of ongoing revenue growth.








ننتقل الى أخبار يوم الخميس

[Sniper]

JADE today announced continuing strong growth in sales and a sharp rise in net income for the third quarter, ending September 30, 2003.


Third Quarter Highlights
Revenues exceed guidance; year-over-year acceleration continues

Net income triples

Nine-month revenue up 22% over 2002

Q4 results to be bolstered by new customer orders
Revenues for the third quarter of 2003 were $16.9 million, up 37% from $12.4 million in the same quarter a year earlier. This was 9% over the high end of earlier guidance of $15.5 million and it marked the third quarter in which year-over-year revenue growth exceeded 20%.

For the third quarter, the company achieved net income of $701,000, or $0.07 per diluted share, up from $232,000, or $0.03 per diluted share, in the third quarter of 2002. For the first nine months of 2003, net income was $1.2 million, or $0.12 per diluted share, up from a loss of ($7.5 million), or ($0.87) per diluted share in the comparable period of 2002.

JADE’s Chairman and CEO Yu Chuan Yih said, "LJ International's third quarter results show the continuing successful progress of our strategy to return the company to its high historic growth rates. Following the cost-cutting and organizational improvements in the prior two years, the company in 2003 has been aggressively working to expand distribution channels and capture new markets with new product lines. Toward that end, we booked substantial new orders with two of the largest TV shopping channels in the U.S., and we opened a new U.S. office for both sales and investor relations."


"At the same time," Mr. Yih continued "we have begun to establish our retail presence in the vast and growing Chinese consumer market. Our aim is to eventually recreate or exceed the growth there that we have experienced in the U.S. With a worldwide sales effort now under way, we expect our revenue growth going forward to stay well into the double-digit levels we have seen this year."

[Sniper]

XYBR today announced their fiscal results for the third quarter ended September 30, 2003. Total revenue for the third quarter of 2003 was $2.7 million, a 6% increase from the same period in 2002. These results represent the second highest levels of both U.S. revenues as well as worldwide consulting revenues in the company's history.


At September 30, the company had no long-term debt, record
quarter-end cash of over $13 million and record
stockholders' equity of over $17 million.
The net loss for the third quarter of 2003 decreased 41% to $4.7 million from the third quarter of 2002. The net loss per share also decreased to $0.03 per share from $0.10 per share in the prior year.


Thomas D. Davis, CFO, noted, "Our cash and stockholders equity balances are both at record levels, we have no long term debt and we have successfully cut costs for seven consecutive quarters. I continue to believe that we have the strongest financial position since our IPO."
"Perhaps one of the best measures of our success is our ability to replicate customer wins in strategic markets," stated Steven A. Newman, President of XYBR. "For example, since the Company's inception, we have secured hardware and services contracts in the transportation sector, alone, surpassing more than $10 million. This focused approach is also producing similar strong results in many other targeted industries. Our future has never looked brighter

[Sniper]

JMAR today reported their results for the third quarter of 2003 ended September 30. The company reported a net loss for the quarter ended September 30, 2003 of $624,161, compared to a net loss for the quarter ended September 30, 2002 of $2,836,656.

Revenue for the three months ended September 30, 2003 declined 39% to $3,964,930 from revenues of $6,462,633 in the corresponding quarter of 2002. For the nine months ended September 30, 2003, revenues declined 6% to $13,726,298 from $14,656,910 in the comparable period of 2002.

Ronald A. Walrod, JMAR's CEO said, "The anticipated financial consequence of the tough but necessary action we took earlier in the year to sell JPSI and reduce staff is now starting to show up as a significant improvement to our bottom line. Over the past quarter, JMAR has become a leaner, more focused company and management will continue to act aggressively to align JMAR's cost structure to its revenue base."


JMAR CFO, Dennis E. Valentine commented, "The significant improvement in the bottom line for the third quarter of 2003 as compared to both the second quarter of 2003 and the corresponding quarter of 2002, is a strong indicator of the positive actions taken by management in the last year. That this improvement came despite lower revenues is particularly noteworthy."

[Sniper]

PDYN's share price has been climbing sharply all day on news that the company has joined an interoperability testing program for voice over Internet protocol (IP) networks and multimedia applications with Nortel Networks.

Nortel has completed interoperability testing with several leading third party vendors, and is either in the process of testing or working towards interoperability testing with several others. The company has initiated testing between PDYN's CPX 1000 voice access gateway and their own softswitch portfolio.

In trading today, PDYN's share price has risen 82 cents to $4.50; trouncing their previous 52-week high of $3.93. Today's new high also represents an increase of 148.6% over our initial profile price of $1.81.

[Sniper]

After the markets closed yesterday CVGR announced their fiscal results for the third quarter ended September 30, 2003. Net revenue for the quarter was $3.9 million as compared to the $6.0 million reported for the same period last year.

The net loss for the quarter was $392 thousand, compared to net income of $380 thousand, for the same period last year. The results largely reflect the impact of lower than anticipated levels of new business awards in the first nine months of the year, the winding down of several larger studies in the later stages of their development cycles and increases to the estimated costs to complete several studies.


Kenneth M. Borow, M.D., President and CEO, commented, "We remain very optimistic regarding the future. The results for the quarter reflect the impact of experiencing a slow period for our Company. We have maintained tight control over operating expenses during this period. At the same time, we have endeavored to position ourselves to take full advantage of opportunities as market conditions improve."
Earlier this morning CVGR announced that the landmark results of the REVERSAL Trial were presented yesterday in Orlando at the 2003 Scientific Sessions of the American Heart Association (AHA).

As reported in a front page article in today's New York Times, entitled Study of Two Cholesterol Drugs Finds One Halts Heart Disease, "The first study to compare two powerful cholesterol-lowering drugs head-to- head in coronary artery disease finds one clearly superior. In patients taking Pravachol, made by Bristol-Myers Squibb, atherosclerosis worsened slowly over 18-months. But the disease was halted in those who took the highest dose of Lipitor, the drug made by Pfizer."

Kenneth M. Borow, M.D., CVGR’s President and CEO, commented, "Covalent is exceptionally proud of our association with the REVERSAL study. As the clinical research organization for REVERSAL, Covalent was intimately involved with Dr. Nissen in the trial's conceptualization, design and writing, operational management and data flow processes."

[Sniper]

EDSN announced yesterday that its shareholders approved a merger agreement to take the company private with a company formed by an affiliate of Liberty Partners, a New York based private equity firm, and H. Christopher Whittle, EDSN’s Founder and CEO.

Over 80% of the roughly 55 million votes cast supported the merger to take the company private. Approximately 14 million votes were not cast. The final percentage of outstanding votes cast in favor of the merger was 65.7%.

"Today's vote is an important step in an exciting new chapter in Edison's history," said Mr. Whittle. "As we return to being a private company, Edison's mission -- to help our partners provide a world-class education to every child we serve -- remains unchanged. We will continue to partner with school districts, charter boards, public school teachers, and community organizations to raise student achievement through schools and programs."

[Sniper]

SWEB today announced its third quarter results for the period ending September 30, 2003.


Third Quarter Highlights
Revenue increased 32%

Gross profit increased 74%

Paid off all outstanding notes to become debt free

Fourth consecutive quarter of increasing revenues and gross profits


2003 third quarter revenues were $745,801, up 32% from the same quarter in 2002. Third quarter gross profit is $595,272, up 74% from the same quarter in 2002. For the nine months ended Sept 30, 2003 revenues increased 44% to $2,036,042, and the nine-month's period gross profit is up 81% to $1,551,827.

As of September 30, 2003 the company had cash and cash equivalents of $860,064, compared to $553,358 on June 30, 2003. The company has no debt, compared to $1,764,862 of debt at September 30, 2002.


"During Q3 Stockgroup became debt free, institutional investors started buying our shares again, and we began seeing the results of our partnership with Associated Press", said Marcus New, Chairman and CEO of SWEB. "The Company's results for Q3 represent a continuing trend for Stockgroup as revenues continue to increase incrementally and profitability remains a core focus."

[Sniper]

ADSX today announced its fiscal results for the third quarter ended September 30, 2003. The consolidated net loss for the three-month period was $1.2 million, a sharp reduction from the net loss of $5.9 million, for the year-ago quarter.

Revenue for the third quarter was $23.8 million, compared with $24.2 million for the year-ago quarter. On a sequential basis, revenue increased 14%, or $2.9 million, and net worth rose $5.3 million since the second quarter of 2003.

For the nine months ended September 30, 2003, the company reported revenue of $69.8 million and net income of $28.3 million. In comparison, the company reported revenue for the nine months ended September 30, 2002, of $78.4 million, and a net loss of $49.8 million.


Commenting on the third-quarter results, Scott R. Silverman, Chairman and CEO, said: "We believe these results represent an important milestone for the Company. Exclusive of Digital Angel Corporation's operating results, the Company achieved net income of over $750,000. The work of restructuring our balance sheet has played an important role in this turn-around."

[Sniper]

Before the markets opened today TTP reported its financial results for the third quarter and first nine months of 2003.

Operating expenses for the third quarter of 2003 decreased approximately 24% to $6.5 million compared with operating expenses of $8.5 million for the third quarter of 2002. For the first nine months of 2003, operating expenses were approximately $20.5 million, a reduction of $5.0 million compared with operating expenses of $25.5 million for the first nine months of 2002.

Revenues for the first nine months of 2003 were $28,000, compared to approximately $2.7 million for the same nine-month period in 2002. The difference in revenue is primarily due to a milestone payment TTP received from Schering AG for Spheramine in the first quarter of 2002.


"Our reduction in operating expenses on a quarter-over-quarter basis is in line with our strategic focus for the reporting period," stated Dr. Louis R. Bucalo, Chairman, President and CEO, "and has enabled the Company to maximize its cash position, while advancing progress in our core development programs."

[Sniper]

USPL also announced its operating results for the three and nine months ended September 30, 2003. Revenues for the third quarter of 2003 were $8.0 million compared with $10.6 million for the same quarter in 2002, a decrease of 25%. The decrease was mainly due to lower sales of the company's building products and the sale of the Cornerboard packaging division in May of 2003.

Revenues for the first nine months of 2003 were $28.9 million compared with $39.8 million for the same period in 2002, a decrease of 27%. The company attributed part of this decrease to not having sufficient inventory to meet the demand for its building products during the first nine months of 2003, mainly due to cash constraints and slower production rates of some of its newly formulated decking products.

Mark Alsentzer, Chairman, CEO and President of USPL said, "We are pleased to see the improvements as a result of the cost reduction initiatives that we implemented at the end of last year. The company is aggressively pursuing opportunities to further improve its balance sheet and its access to capital to enable it to meet the growing product demand and improve its overall operating performance."


He concluded, "We believe that the demand for alternative wood products has never been stronger and reductions in costs position the Company well to re-gain profitability with increasing sales."
In addition, the company today announced that it has recently re-opened the Ocala facility on a limited production basis; which the company announced in August was temporarily shut down due to an explosion outside the plant. USPL anticipates the facility to be at full production by the end of January 2004

[Sniper]

We first introduced you to MITK back on September 3 when the company was trading for $1.10; by November 6, the company’s share price had risen 201% to $3.32.

On October 31 it was reported that The Wachovia Bank, using MITK technology, was bringing a new security fraud system onto the market. Before the press release the company was trading for as low as $1.40; within a few days the company’s share price had climbed 192% to $3.32.

After sustaining those highs for a week the company’s share price gave up some ground to profit taking, falling to a low of $2.11.

On Tuesday though, MITK reported that they will be announcing their financial results for the fiscal fourth quarter and year end September 30, 2003 on Tuesday, November 18, 2003. Speculating strong results, investors have sent MITK’s share price up 43% since yesterday to a high today of $3.02.

[Sniper]

After the markets close yesterday ZONS announced its results for the third quarter ended September 30, 2003.

Total net sales rose 10% to $112.7 million in the third quarter of 2003 compared to $102.4 million in the third quarter of 2002. The company reported net income of $134,000, for the third quarter of 2003 compared with net income of $124,000, for the same quarter a year ago.

Net sales for the nine months ended September 30, 2003 were $330.4 million compared to $310.0 million for the corresponding period of the prior year. The net loss for the nine months ended September 30, 2003 was $636,000 or $.05 per share compared to net earnings in the first nine months of 2002 of $577,000, or $0.04 per share.

[Sniper]

On Friday afternoon SNTK released their fiscal results for the third quarter and nine months ended September 30, 2003.

Revenues for the third quarter ended September 30, 2003 were approximately $2.2 million, 5.5% higher than the quarter ended September 30, 2002. SNTK also announced a net loss for the third quarter of $1,102,000 or $ .02 per fully diluted share, compared to net income of $207,000 and $0.00 per share in the third quarter of 2002.

For the nine months ended September 30, 2003, SNTK reported revenue of $5.8 million compared to $7.8 million in the period ended September 30, 2002. For the nine months ended September 30, 2003, the company incurred a net loss of $2,042,000 or $.03 per fully diluted share, compared to net income and fully diluted earnings per share of $1,881,000 and $.03 in the nine months ended September 30, 2002.

The decline in net income and earnings per share in the three and nine months ended September 30, 2003 is primarily due to reduced Kinetin royalty revenue, higher administrative, sales and marketing expenses, higher research and development expenses, and non-recurring interest expense related to the debt refinancing in September 2003.

Product sales for the three and nine months ended September 30, 2003 were $455,000 and $549,000 higher than the comparable periods in 2002. The majority of SNTK's product sales are from Valeant Pharmaceuticals International, Inc. The increase in Valeant's revenue is the result of a recently signed expanded license agreement with Valeant that will add five new products to its existing Kinerase product line.